KB Home
KBH
Ecopetrol
EC
Petroleo Brasileiro SA Petrobras
PBR
4
Vale SA
VALE
5
Taylor Morrison Home
TMHC
US Stock MarketDetailed Quotes
MLYS Mineralys Therapeutics
- 16.150
- -0.630-3.75%
Close Mar 26 16:00 ET
- 16.150
- 0.0000.00%
Post 16:05 ET
1.01BMarket Cap-4.41P/E (TTM)
17.210High15.940Low1.32MVolume16.780Open16.780Pre Close21.38MTurnover3.45%Turnover RatioLossP/E (Static)62.80MShares18.38052wk High5.30P/B616.79MFloat Cap8.24152wk Low--Dividend TTM38.19MShs Float21.980Historical High--Div YieldTTM7.57%Amplitude5.850Historical Low16.247Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
Mineralys Therapeutics Stock Forum
03/10/2025 - 04:00 AM
– Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by automated office blood pressure at week 6 –
– Launch-HTN met a predefined endpoint with lorundrostat 50 mg dose achieving a 19.0 mmHg reduction in systolic blood pressure, and an 11.7 mmHg placebo-adjusted reduction (p-value < 0.0001) asse...
I find this to be very shady
I'm staying away from this one good luck people
Why am I unable to find any information about this phase 2 trial for this drug it just does it say unless I'm missing it I don't see where they gave the report for phase 2
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you...
Mineralys Therapeutics to Announce Topline Data From Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
GlobeNewswire· 13:012mins
Mineralys Therapeutics(MLYS.US)
RADNOR, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (...
and MLYS $Mineralys Therapeutics (MLYS.US)$ are my money makers
$Meta Platforms (META.US)$ +2% (A Bloomberg report announced that the company is planning another round of layoffs as soon as this week. The company previously cut 13% of its workforce in November as part of CEO Mark Zuckerberg's efforts to make the company more profitable.)
$WW International (WW.US)$ +17.6% (The company formerly known as Weight Watchers announced a deal to acquire telehealth firm Sequence. The move could he...
No comment yet